According to Matthijs Van Meerveld, “The right medicine for the right patient at the right time is a notion all stakeholders easily subscribe to, but it is far from easy to achieve this in practice. At Menarini Stemline our rapidly growing team of decidated pharma professionals is committed to addressing unmet needs in hematology with our medicines for the treatment of multiple myeloma and the rare disease Blastic plasmacytoid dendritic cell neoplasm (BPDCN). The EHA congress in Frankfurt provided an excellent opportunity to enhance our understanding of the optimal treatment of people living with these diseases, and to forge collaborations on advancing access to treatment. The ever evolving science is breathtaking, and we should never stop our efforts to provide the right patient with the right medicine at the right time”.
Source: Matthijs Van Meerveld/Linkedin
